Clinical trials: Addiction, Substance
Opioid-use Disorder
Treatment for Opiate Addiction: Prognostic fActors of Responsiveness to Maintenance Treatment
A global and integrative treatment of opioid-use disorders (OUD) with opiate maintenance therapy (OMT) and psychosocial interventions is recommended by all current guidelines.
- Trial name
- TOPAZE (NCT03729388)
- Testing
- Prognosis factor associated with good outcome.
- Where
- 2 sites in France
- Volunteers
- 29 people
- Sponsor
- Nantes University Hospital
Cocaine Addiction
Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
The primary objective of this study is to assess the efficacy and safety of TV-1380 [Recombinant human serum albumin (HSA) mutated butyrylcholinesterase (AlbuBChE)] in facilitating abstinence in cocaine-dependent subjects.
- Trial name
- NCT01887366
- Testing
- TV-1380 150 mg, TV-1380 300 mg
- Where
- 19 sites in United States, Spain
- Volunteers
- 208 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Community Reinforcement And Family Training, Family Health
Scalable Digital Delivery of Evidence-based Training for Professionals to Maximize Treatment Rates of OUD in Families
The goal of this project is to develop and evaluate the technical feasibility and commercial viability of a scalable digital counselor training program for CRAFT.
- Conditions
- Community Reinforcement And Family Training, Family Health, Substance-Related Disorders
- Trial name
- NCT05875142
- Testing
- Behavioral: Digital Tutorial Overview, Behavioral: Training Materials, Behavioral: Feedback and Coaching
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- We The Village, Inc.
Opioid Use Disorder
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention.
- Trial name
- SARA RCT (NCT06732596)
- Testing
- Embodied conversational agent (ECA), Technical support, Additional ECA messages
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Boston Medical Center
Depression, Marijuana Abuse
Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1
The purpose of this study is to determine if Venlafaxine Extended Release (Ven-XR) is effective in treating individuals with marijuana addiction and depression.
- Trial name
- VEN (NCT00131456)
- Testing
- Venlafaxine
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- New York State Psychiatric Institute
Hepatitis C, Chronic, Hepatitis C
A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic
The main purpose of this pilot study is to investigate the safety, effectiveness and tolerability of the study medication in the treatment of people with chronic hepatitis C virus infection who regularly attend a…
- Conditions
- Hepatitis C, Chronic, Hepatitis C, Opiate Dependence
- Trial name
- NCT03235154
- Testing
- sofosbuvir/velpatasvir
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Community Research Initiative of New England
HIV Infection, Pain
Targeting Effective Analgesia in Clinics for HIV - Patient Cohort
The TEACH patient cohort will characterize a clinic sample of HIV-infected patients on chronic opioid therapy (COT) by describing basic demographics and health status, including characteristics of pain (severity and…
- Conditions
- HIV Infection, Pain, Drug Dependence
- Trial name
- TEACH (NCT02525731)
- Where
- 2 sites in United States
- Volunteers
- 170 people
- Sponsor
- Boston Medical Center
Opiate Dependence
Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
The purpose of this study is to evaluate a very low dose naltrexone-buprenorphine treatment to transfer opioid dependent individuals to extended release naltrexone injection (Vivitrol).
- Trial name
- BUP/NXT-VIVI (NCT01690546)
- Testing
- very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Paolo Mannelli
Opioid Abuse, Opioid Addiction
The Discriminative Effects of Tramadol in Humans
This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram.
- Conditions
- Opioid Abuse, Opioid Addiction, Stimulant Abuse, Stimulant Addiction
- Trial name
- NCT00499746
- Testing
- tramadol, Hydromorphone, Methylphenidate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Intimate Partner Violence, Substance Abuse/Addiction
Intimate Partner Violence and Fatherhood Intervention in Residential Substance Abuse Treatment
The proposed stage 1 intervention development study is designed to address two significant co-occurring issues for fathers with substance abuse (SA) problems: Intimate partner violence (IPV) and child maltreatment (CM).
- Conditions
- Intimate Partner Violence, Substance Abuse/Addiction, Child Maltreatment
- Trial name
- NCT02979262
- Testing
- Fathers for Change, Parent Education
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of South Florida
Transdiagnostic, Depression - Major Depressive Disorder
Open-Label Psilocybin Study in Transdiagnostic Population
The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms.
- Conditions
- Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms
- Trial name
- NCT06442423
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University
Heroin Dependence, Opiate Dependence
Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction
The planned research will adapt an intervention of known efficacy to target a new outcome of significant importance to public health.
- Conditions
- Heroin Dependence, Opiate Dependence, Substance Dependence
- Trial name
- NCT00609089
- Testing
- CRAFT-T, Treatment as usual
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Cincinnati
Smoking Cessation, Nicotine Addiction
Nicotine Receptor Levels and Smoking Cessation
The investigators propose to use positron emission tomography (PET) imaging to determine whether nicotinic receptor availability at pretreatment predicts smoking cessation success.
- Trial name
- NCT01788943
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Heroin Dependence
Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts
Naltrexone is a medication that is currently used to treat drug and alcohol addiction. Guanfacine is a medication that is currently used to manage the withdrawal symptoms in individuals undergoing opioid detoxification.
- Trial name
- NCT00142948
- Testing
- Naltrexone
- Where
- Russia
- Volunteers
- 301 people
- Sponsor
- Baylor College of Medicine
Tobacco Smoking, Electronic Cigarette Use
Dual Use Approach Bias Training for Nicotine Addiction
The present project will evaluate the initial efficacy of approach bias retraining among dual combustible cigarette (CC) and electronic cigarette (ECIG) users.
- Conditions
- Tobacco Smoking, Electronic Cigarette Use, Substance Use
- Trial name
- NCT05306158
- Testing
- CC+ECIG Condition, CC Condition
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Houston
Cocaine-Related Disorders
Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1
Recent findings have suggested that N-acetylcysteine (NAC) substantially reduces cocaine drug-seeking behavior in formerly cocaine dependent rats.
- Trial name
- NCT00136825
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Chronic Pain, Opioid Use Disorder
Combined THC and CBD for OUD and Chronic Pain
The primary objective of this phase 2 study is to investigate the therapeutic potential of orally administered combined delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in relieving both pain and cue-induced opioid…
- Trial name
- NCT06544291
- Testing
- CBD 300mg, CBD 600mg
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Yale University
Substance Abuse
Positive Effects of Laser Acupuncture in Methamphetamine Users Undergoing Group Cognitive Behavioral Therapy: A Pilot Study
Methamphetamine (MA) addiction has become a crucial public health issue due to its adverse effects. Acupuncture has been used for drug detoxification for many years. However, some disadvantages are not be suitable for MA users.
- Trial name
- NCT04789772
- Testing
- Laser acupuncture
- Where
- 2 sites in Taiwan
- Volunteers
- 15 people
- Sponsor
- Chang Gung Memorial Hospital
Alcohol Use Disorder (AUD)
AAT-App Outpatient Trial
Cognitive biases contribute to the difficulty experienced by heavy drinkers wishing to reduce their alcohol use. Recent interventions designed to reduce cognitive biases demonstrate efficacy for Approach Bias Modification (ApBM).
- Trial name
- AAT-App (NCT05120856)
- Testing
- AAT-App, Minimal AAT-App
- Where
- 6 sites in Australia
- Volunteers
- 82 people
- Sponsor
- Turning Point
Nicotine Addiction
Pharmacogenetics of Nicotine Addiction Treatment
The purpose of this research program is to understand how a biomarker called the "nicotine metabolite ratio" (also referred to as NMR) may influence a smoker's ability to quit smoking.
- Trial name
- NCT01314001
- Testing
- Varenicline, Transdermal Nicotine
- Where
- 4 sites in United States, Canada
- Volunteers
- 1,246 people
- Sponsor
- University of Pennsylvania